Sugi Predict

Sugi Predict / Compounds / SCHEMBL193290

SCHEMBL193290

SCHEMBL193290

O=S(=O)(O)CCCCOCCCCS(=O)(=O)O.[NaH].[NaH]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.46
▸ LMNA P02545 4/20 0.38
▸ BLM P54132 2/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ SLC6A6 P31641 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.32
▸ POLB P06746 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ ALOX15 P16050 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ HTT P42858 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ BRCA1 P38398 1/20 0.32
▸ GMNN O75496 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ THPO P40225 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312671 1.00 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL37545 0.97 APP (0.48) APPLMNABLMPTGS1PDE4A
SCHEMBL30782568 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL30133577 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL420986 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
Bromide SCHEMBL31659017 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL419968 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL754172 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL18380848 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL754168 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10117951-B2 Sulfoalkyl ether cyclodextrin compositions CYDEX PHARMACEUTICALS, INC. (US) 2018-11-06 — — US claimed
US-20240228446-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD (CN) 2024-07-11 — — US disclosed
CN-112512529-B Cyclopentenepurine derivative or salt thereof 富士胶片株式会社 2024-06-18 — — CN disclosed
CN-117982682-A Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections 吉利德科学公司 2024-05-07 — — CN disclosed
CN-110575762-B Preparation method of organic alkyl gadolinium aqueous dispersion system 温州大学新材料与产业技术研究院 2024-03-26 — — CN disclosed
CN-111093627-B Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections 吉利德科学公司 2024-03-08 — — CN disclosed
EP-4317139-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2024-02-07 — — EP disclosed
CN-117500843-A Purification of sulfobutylated cyclodextrins with specific ion exchange resins CYCLOLAB 环糊精研发实验室有限公司 2024-02-02 — — CN disclosed
CN-112351985-B Pyridopyrimidinone derivatives as AXL inhibitors 奥斯考泰克公司 2023-12-15 — — CN disclosed
US-11806402-B2 Sulfoalkyl ether cyclodextrin compositions CYDEX PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
WO-2011137459-A1 DOSAGE FORMS OF ELINOGREL AND METHODS OF INJECTABLE ADMINISTRATION THEREOF PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-03 — — WO disclosed
EP-2268269-A2 SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS CyDex Pharmaceuticals, Inc. (US) 2011-01-05 — — EP disclosed
WO-2010097700-A1 BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS SUPRATEK PHARMA, INC. (CA) 2010-09-02 — — WO disclosed
US-20100216858-A1 BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS SOFTKEMO PHARMA CORP. (CA) 2010-08-26 — — US disclosed
US-20100093663-A1 Sulfoalkyl Ether Cyclodextrin Compositions CYDEX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-7635773-B2 Sulfoalkyl ether cyclodextrin compositions CYDEX PHARMACEUTICALS, INC. (US) 2009-12-22 — — US disclosed
WO-2009134347-A2 SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS CYDEX PHARMACEUTICALS, INC. (US) 2009-11-05 — — WO disclosed
US-20090270348-A1 Sulfoalkyl Ether Cyclodextrin Compositions CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2009-10-29 — — US disclosed
EP-1614432-A2 Method for treating amyloidosis QUEEN'S UNIVERSITY AT KINGSTON (CA) 2006-01-11 — — EP disclosed
EP-0503674-A1 Light-sensitive bistrihalomethyl-S-triazine compound and photopolymerizable composition containing same FUJI PHOTO FILM CO., LTD. (JP) 1992-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228446-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT ERG28, CYP51A1, DPM1 APP 2722/4885LMNA 2232/4885BLM 3467/4885
US-20090270348-A1 Sulfoalkyl Ether Cyclodextrin Compositions SI, SULT1E1, SAE1 APP 1156/4885LMNA 2712/4885BLM 852/4885
US-10117951-B2 Sulfoalkyl ether cyclodextrin compositions SI, SULT1E1, SAE1 APP 1370/4885LMNA 2765/4885BLM 678/4885
US-20100093663-A1 Sulfoalkyl Ether Cyclodextrin Compositions SI, SULT1E1, SAE1 APP 1370/4885LMNA 2765/4885BLM 678/4885
US-11806402-B2 Sulfoalkyl ether cyclodextrin compositions SI, SULT1E1, SAE1 APP 1370/4885LMNA 2765/4885BLM 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.